TMCnet - World's Largest Communications and Technology Community



Research and Markets: Phosphodiesterase 4 (PDE-4) Inhibitors Competitor Analysis 2014
[June 30, 2014]

Research and Markets: Phosphodiesterase 4 (PDE-4) Inhibitors Competitor Analysis 2014

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors" report to their offering.

PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and odulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects.

Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer's disease are also studied clinically as indications for PDE-4 inhibitors.

The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target (News - Alert) / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage and additional comments with a hyperlink leading to the source of information

Key Topics Covered:

1. Oral and Inhaled Non-Selective PDE-4 Inhibitors

2. Oral and Inhaled Seletive PDE-4 Inhibitors

3. Topical PDE-4 Inhibitors

4. Corporate PDE-4 Inhibitor R&D Pipelines

Companies Mentioned

  • Alcon (a Novartis company)
  • Almirall
  • Anacor Pharmaceuticals
  • c-a-i-r Biosciences
  • Celgene
  • Chiesi Farmaceutici
  • Dainippon Sumitomo Pharma
  • Dart NeuroScience
  • Dermira
  • Eisai
  • Forest Laboratories
  • Gilead Sciences
  • GlaxoSmithKline
  • Kyorin Pharmaceutical
  • Maruho
  • MediciNova
  • Merck
  • Michael J. Fox Foundation
  • Orchid Chemicals & Pharmaceutical
  • Otsuka Pharmaceutical
  • Pharmaxis Sanofi
  • Takeda Pharmaceutical Co (Nycomed)
  • Tetra Discovery Partners
  • Verona Pharma

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy